These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 28710251)

  • 1. Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
    Skopelja-Gardner S; Jones JD; Hamilton BJ; Danilov AV; Rigby WFC
    J Immunol; 2017 Aug; 199(4):1275-1282. PubMed ID: 28710251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.
    Bologna L; Gotti E; Manganini M; Rambaldi A; Intermesoli T; Introna M; Golay J
    J Immunol; 2011 Mar; 186(6):3762-9. PubMed ID: 21296976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.
    Beum PV; Peek EM; Lindorfer MA; Beurskens FJ; Engelberts PJ; Parren PW; van de Winkel JG; Taylor RP
    J Immunol; 2011 Sep; 187(6):3438-47. PubMed ID: 21841127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.
    Patz M; Isaeva P; Forcob N; Müller B; Frenzel LP; Wendtner CM; Klein C; Umana P; Hallek M; Krause G
    Br J Haematol; 2011 Feb; 152(3):295-306. PubMed ID: 21155758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies.
    Valgardsdottir R; Cattaneo I; Klein C; Introna M; Figliuzzi M; Golay J
    Blood; 2017 May; 129(19):2636-2644. PubMed ID: 28288980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes.
    Beum PV; Mack DA; Pawluczkowycz AW; Lindorfer MA; Taylor RP
    J Immunol; 2008 Dec; 181(11):8120-32. PubMed ID: 19018005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab.
    Felberg A; Taszner M; Urban A; Majeranowski A; Jaskuła K; Jurkiewicz A; Stasiłojć G; Blom AM; Zaucha JM; Okrój M
    Front Immunol; 2020; 11():584509. PubMed ID: 33329558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.
    Tobinai K; Klein C; Oya N; Fingerle-Rowson G
    Adv Ther; 2017 Feb; 34(2):324-356. PubMed ID: 28004361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia.
    Laprevotte E; Ysebaert L; Klein C; Valleron W; Blanc A; Gross E; Laurent G; Fournié JJ; Quillet-Mary A
    Leuk Res; 2013 Apr; 37(4):440-6. PubMed ID: 23259986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties.
    Rafiq S; Butchar JP; Cheney C; Mo X; Trotta R; Caligiuri M; Jarjoura D; Tridandapani S; Muthusamy N; Byrd JC
    J Immunol; 2013 Mar; 190(6):2702-11. PubMed ID: 23418626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab.
    Yasuhiro T; Sawada W; Klein C; Kozaki R; Hotta S; Yoshizawa T
    Leuk Lymphoma; 2017 Mar; 58(3):699-707. PubMed ID: 27684575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model.
    Marinov AD; Wang H; Bastacky SI; van Puijenbroek E; Schindler T; Speziale D; Perro M; Klein C; Nickerson KM; Shlomchik MJ
    Arthritis Rheumatol; 2021 May; 73(5):826-836. PubMed ID: 33277983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101.
    Jak M; van Bochove GG; Reits EA; Kallemeijn WW; Tromp JM; Umana P; Klein C; van Lier RA; van Oers MH; Eldering E
    Blood; 2011 Nov; 118(19):5178-88. PubMed ID: 21948297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.
    Skarzynski M; Niemann CU; Lee YS; Martyr S; Maric I; Salem D; Stetler-Stevenson M; Marti GE; Calvo KR; Yuan C; Valdez J; Soto S; Farooqui MZ; Herman SE; Wiestner A
    Clin Cancer Res; 2016 Jan; 22(1):86-95. PubMed ID: 26283682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice.
    Boross P; Jansen JH; Pastula A; van der Poel CE; Leusen JH
    Immunol Lett; 2012 Mar; 143(1):44-52. PubMed ID: 22285696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
    Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
    Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of Trogocytosis: Quantitative Analyses Validated with Rigorous Controls.
    Taylor RP; Lindorfer MA
    Curr Protoc; 2023 Oct; 3(10):e897. PubMed ID: 37830752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling.
    Dielschneider RF; Xiao W; Yoon JY; Noh E; Banerji V; Li H; Marshall AJ; Johnston JB; Gibson SB
    Cell Death Dis; 2014 Oct; 5(10):e1439. PubMed ID: 25275600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical application of obinutuzumab for treating chronic lymphocytic leukemia.
    Luan C; Chen B
    Drug Des Devel Ther; 2019; 13():2899-2909. PubMed ID: 31692500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells.
    Cavallini C; Galasso M; Pozza ED; Chignola R; Lovato O; Dando I; Romanelli MG; Krampera M; Pizzolo G; Donadelli M; Scupoli MT
    Br J Haematol; 2021 Jan; 192(2):333-342. PubMed ID: 33216963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.